title: Estrogen with interrupted progestin HRT: a review of experimental and clinical studies.
abstract: This review outlines the basic principles of a novel interrupted progestin HRT regimen in which estrogen is administered continuously, and progestin is given in a 3-days on, 3-days off pulsed fashion. The rationale for this regimen is to prevent receptor down-regulation and allow increased estrogen and progestin sensitivity during the progestin-free periods. Background information is provided including the reasons for poor patient acceptance of HRT, and the concerns of the potential association of HRT with breast and endometrial cancer. Experimental studies in the rat are described which provide evidence in support of the rationale for the interrupted progestin regimen. Clinically, two pilot studies examining symptom control, bleeding rates and safety of the interrupted progestin regimen, as well as preliminary results of a third study examining the usefulness of this regimen for addback therapy in GnRH agonist treated patients, are outlined. The preliminary results of phase III trials are presented. These clinical studies all demonstrated good symptom control, low bleeding rates, endometrial protection, and excellent patient acceptance. The combination of continuous estrogen with interrupted progestin appears to result in increased sensitivity to estrogen and progestin in estrogen responsive tissues. As a result, lower doses of estrogen and progestin may be used for HRT with good biological effects. Further clinical studies, preferably in prospective randomized trials, are required to demonstrate an advantage of this new regimen compared to continuous combined HRT.
authors.affiliation: Department of Obstetrics and Gynecology, The University of Toronto, Ont., Canada. r.casper@utoronto.ca
authors.forename: R F
authors.initials: RF
authors.lastname: Casper
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000139:chemically induced; D017326:Clinical Trials, Phase III as Topic; D015536:Down-Regulation; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D010349:Patient Compliance; D010865:Pilot Projects; D011372:Progestins / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D011980:Receptors, Progesterone / Q000187:drug effects
chemical_list: D004967:Estrogens; D011372:Progestins; D011980:Receptors, Progesterone; D007987:Gonadotropin-Releasing Hormone